The FDA has deemed marketing materials touting Latisse, the newly released prescription eyelash thickener marketed by Allergan, as “misleading.” The FDA stated that Latisse ads omit and minimize risks associated with the product, such as redness and eye color changes. According to Reuters, the FDA has asked Allergan to immediately stop using the materials. Dow Jones has explained that the eye infection, bacterial keratitis, can cause blindness.